Paxalisib targeting PI3K/mTOR pathway for nGBM patients with unmethylated MGMT

Paxalisib targeting PI3K/mTOR pathway for newly-diagnosed GBM patients with unmethylated MGMT promotor
From Kazia Web site:
"Paxalisib is completing a phase II study in patients with newly-diagnosed glioblastoma who have a genetic marker called an unmethylated MGMT promotor. This group represents approximately two-thirds of glioblastoma cases, and is almost entirely unresponsive to temozolomide, the only FDA-approved drug treatment for newly-diagnosed patients"

Chinese Journal of Cancer Research, Vol 33, No 3 June 2021
Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286895/pdf/cjcr-33-3-417.pdf

Targeted therapy aimed at other targets
"Phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) is a frequently activated pathway and plays an important role in tumor proliferation"

"Despite these setbacks, trials on promising new agents are ongoing. GDC-0084 is a selective PI3K/mTOR pathway multi-targeted inhibitor that demonstrated tumor inhibition and favorable BBB-penetrating ability in a phase I trial (46). In a two-arm phase II trial (NCT03522298), the efficacy of GDC-0084 was compared with that of temozolomide in nGBMs, and the interim report yielded positive results. In the exploration of therapies targeting the PI3K pathway, GDC-0084 is currently the most promising agent, and the above-mentioned phase II trial may provide a specific therapeutic effect for patients with PI3K pathway activation".

Thank you Rinnekin for your post on **promotion blocked**, and may explain why Simcere was so keen to secure the license of paxalisib in Greater China in March 2021.

Regards.